Publication:
Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis

dc.contributor.authorCharat Thongprayoonen_US
dc.contributor.authorWisit Kaewputen_US
dc.contributor.authorSpencer T. Hatchen_US
dc.contributor.authorTarun Bathinien_US
dc.contributor.authorKonika Sharmaen_US
dc.contributor.authorKarn Wijarnpreechaen_US
dc.contributor.authorPatompong Ungpraserten_US
dc.contributor.authorMatthew D’Costaen_US
dc.contributor.authorMichael A. Maoen_US
dc.contributor.authorWisit Cheungpasitpornen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherPhramongkutklao College of Medicineen_US
dc.contributor.otherMayo Clinicen_US
dc.contributor.otherUniversity of Mississippi Medical Centeren_US
dc.contributor.otherBassett Medical Centeren_US
dc.date.accessioned2020-01-27T07:49:28Z
dc.date.available2020-01-27T07:49:28Z
dc.date.issued2019-02-15en_US
dc.description.abstract© 2018, Springer Science+Business Media, LLC, part of Springer Nature. Background/Objectives: We performed this systematic review and meta-analysis to evaluate effects of probiotics on inflammation, uremic toxins, and gastrointestinal (GI) symptoms in end-stage renal disease (ESRD) patients. Methods: A literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane Database from inception through October 2017. We included studies that assessed assessing effects of probiotics on inflammatory markers, protein-bound uremic toxins (PBUTs), and GI symptoms in ESRD patients on dialysis. Effect estimates from the individual study were extracted and combined utilizing random effect, generic inverse variance method of DerSimonian and Laird. The protocol for this meta-analysis is registered with PROSPERO; No. CRD42017082137. Results: Seven clinical trials with 178 ESRD patients were enrolled. There was a significant reduction in serum C-reactive protein (CRP) from baseline to post-probiotic course (≥ 2 months after treatment) with standardized mean difference (SMD) of − 0.42 (95% CI − 0.68 to − 0.16, p = 0.002). When compared to control, patients who received probiotics also had a significant higher degree of reduction in CRP level with SMDs of − 0.37 (95% CI − 0.72 to 0.03, p = 0.04). However, there were no significant changes in serum TNF-alpha or albumin with SMDs of − 0.32 (95% CI − 0.92 to 0.28, p = 0.29) and 0.16 (95% CI − 0.20 to 0.53, p = 0.39), respectively. After probiotic course, there were also significant decrease in PBUTs and improvement in overall GI symptoms (reduction in GI symptom scores) with SMDs of − 0.61 (95% CI − 1.16 to − 0.07, p = 0.03) and − 1.04 (95% CI − 1.70 to − 0.38, p = 0.002), respectively. Conclusion: Our study demonstrates potential beneficial effects of probiotics on inflammation, uremic toxins, and GI Symptoms in ESRD patients. Future large-scale clinical studies are required to assess its benefits on other important clinical outcomes including patient mortality.en_US
dc.identifier.citationDigestive Diseases and Sciences. Vol.64, No.2 (2019), 469-479en_US
dc.identifier.doi10.1007/s10620-018-5243-9en_US
dc.identifier.issn15732568en_US
dc.identifier.issn01632116en_US
dc.identifier.other2-s2.0-85051744703en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/50256
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85051744703&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleEffects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysisen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85051744703&origin=inwarden_US

Files

Collections